ScripsAmerica, Inc. announced that the company has entered into a joint venture with Global Pharma Hub to license, market and distribute its RapiMed(R) Children's pain reliever and fever reducer. Global Pharma Hub has an exclusive license to market and distribute RapiMed(R) worldwide with the exception of the United States. Additionally, Global Pharma Hub has the ability enter sub-license agreements in the interest of market expansion and revenue generation for RapiMed(R) and has provided a sub-license to NYJJ to generate initial and ongoing orders for the product following its registration approval by the Hong Kong government.

These agreements are the necessary final steps in securing the product's registration approval.